Prof. Dr. Dr. Brigitta Baumert
Gilbert MR, Wang M, Aldape K, Stupp R, Hegi M, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal D, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins K, Tzuk-Shina T, Brown P, Chakravarti A, Curran WJ, Mehta MP. Dose dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial. Accepted for publication in J Clin Oncol 28 June 2013. IF: 18.372
Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, Gaspar LE, Harris GJ, Henson JW, Hodi FS, Kalkanis SN, Lamborn KR, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Sneed PK, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, and Wen PY. Response Assessment in Neuro-Oncology (A Report of the RANO Group): Challenges Relating To Solid Tumor Brain Metastases in Clinical Trials, Part 1: Patient Population, Response, and Progression. Provisionally accepted for publication in The Lancet Oncology 18 June 2013. IF: 21.856
Lin NU, Wefel JS, Lee EQ, Schiff D, van den Bent MJ, Soffietti R, Suh JH, Vogelbaum MA, Mehta MP, Dancey J, Linskey ME, Camidge DR, Aoyama H, Brown PD, Chang SM, Kalkanis SN, Barani IJ, Baumert BG, Gaspar LE, Hodi FS, Macdonald DR, and Wen PY. Response Assessment in Neuro-Oncology (A Report of the RANO Group)Part 2: Neurocognitive, Neurological, and Quality of Life Outcomes. Provisionally accepted for publication in The Lancet Oncology 18 June 2013. IF: 21.856
Bromberg JEC, Baumert BG, de Vos F, Gijtenbeek JMM, Kurt E, Westermann AM, Wesseling P. Primary Intracranial Germ-Cell Tumors in Adults - A Practical Review. Accepted for publication in J Neuro-Oncology 13 March 2013. IF: 5.723
van den Bent MJ, Jaeckle K, Baumert B, Wick W. RTOG 9802: Good Wines Need Aging. J Clin Oncol 10;31(5):653-4 (2013). IF:18.372
Schröer-Günther MA, Wolff RF, Westwood ME, Scheibler FJ, Schürmann C, Baumert BG, Sauerland S, Kleijnen J. F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/CT imaging in primary staging of patients with malignant melanoma: A systematic review. Syst Rev 13;1(1):62 (2012). IF:-
Soffietti R, Kocher M, Abacioglu UM, Villa S, FAUCHON F, Baumert B, Fariselli L, Tzuk-shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den Berge D, Mueller RP, Tridello G, Collette L, Bottomley A. An EORTC Phase III trial of Adjuvant Whole-Brain Radiotherapy Versus Observation in patients with 1 to 3 Brain Metastases From Solid Tumors After Surgical Resection or Radiosurgery: Quality-of-Life analysis, J Clin Oncol 1;31(1):65-72 (2013). IF:18.372
De Ruysscher D, Wanders R, van Baardwijk A, Dingemans AM, Reymen B, Houben R, Bootsma G, Pitz C, van Eijsden L, Geraedts W, Baumert BG, Lambin P. Radical Treatment of Non-Small-Cell Lung Cancer Patients with Synchronous Oligometastases: Long-Term Results of a Prospective Phase II Trial (Nct01282450). J Thorac Oncol 7(10):1547-1555. (2012). IF: 3.661
Narayan RS, Fedrigo CA, Stalpers LJ, Baumert BG, Sminia P. Targeting the Akt-pathway to improve radiosensitivity in glioblastoma. Curr Pharm Des 2013;19(5):951-7. (2013). IF: 4.744
Preusser M, Winkler F, Collette L, Haller S, Marreaud S, Soffietti R, Klein M, Reijneveld JC, Tonn JC, Baumert BG, Mulvenna P, Schadendorf D, Duchnowska R, Berghoff AS, Lin N, Cameron DA, Belkacemi Y, Jassem J, Weber DC. Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. Eur J Cancer 48(18):3439-47 (2012). IF: 5.36
Fairchild A, Collette L, Hurkmans CW, Baumert B, Weber DC, Gulyban A, Poortmans P. Do Results of the EORTC dummy run predict quality of radiotherapy delivered within multicentre clinical trials? Eur J Cancer (17):3232-9 (2012). IF: 5.36
Compter I, Zaugg K, Houben RMA, Dings JTA, Bosmans G, Buescher C, Anten MMHME, Baumert BG. Stereotactic radiotherapy of meningeomas results in high symptom improvement and local control if given early after diagnosis. A multi-centre study. Strahlenther Onkol 188(10):887-893. (2012). IF: 3.561
Fairchild A, Weber DC, Bar-Deroma R, Gulyban A, Fenton PA, Stupp R, and Baumert BG. Quality Assurance in the EORTC 22033-26033/CE5 Phase III Randomised Trial for Low Grade Glioma: The Digital Individual Case Review. Radiother Oncol 103(3):287-92. (2012). IF: 5.580
Wick W, van den Bent M, Vecht C, Brandes A, Lacombe D, Gorlia T, Allgeier A, Baumert BG, Soffietti R, Sanson M, Karim ABMF, Mirimanoff RO, Taphoorn M, Kros M, Hegi M, Stupp R, on behalf of the EORTC Brain Tumor Group. EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology. Eur J Cancer Supplements Vol 10, Issue 1. pp 20-26. (2012). IF: 5.536
Wesseling FWR, de Kunder SL, Schijns OEMG, Baumert BG, Postma AA. Tubular tumor growth along entire biopsy track of brain metastasis. J Thorac Oncol 7(6):1058. (2012). IF: 3.661
Villà S, Miller RC, Krengli M, Abusaris H, Baumert BG, Servagi-Vernat S, Igden S, Lucas A, Boluda S, Mirimanoff RO. Primary Pineal Tumors: Outcome and prognostic factors. A study from the Rare Cancer Network (RCN). Clin Transl Oncol, 2012 Aug 23. IF 1.327
Roelofs E, Engelsman M, Rasch C, Persoon L, Qamhiyeh S, de Ruysscher D, Verhaegen F, Pijls-Johannesma M, Lambin P; ROCOCO Consortium (Baumert B). Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. J Thorac Oncol 7(1):165-76. (2012). IF: 4.040
Brandes AA, Franceschi E, Gorlia T, Wick W, Jacobs AH, Baumert BG, van den Bent M, Weller M, Stupp R; On behalf of European Organisation for Research and Treatment of Cancer Brain Tumour Group. Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma. Eur J Cancer 48:896–903. (2012). IF: 5.36
van de Langenberg R, Dohmen AJC, de Bondt BJ, Nelemans PJ, Baumert BG, Stokroos RJ. Volume Changes after Stereotactic LINAC Radiotherapy in Vestibular Schwannoma: Control Rate and Growth Patterns. Int J Radiat Oncol Biol Phys 84(2):343-9. (2012). IF: 4.105
Mul VEM, de Jong JMA, Murrer LHP, van den Ende PLA, Houben RMA, Lacko M, Lambin P, Baumert BG. Lhermitte sign and myelopathy after irradiation of the cervical spinal cord in radiotherapy treatment of head and neck cancer. Strahlenther Onkol 188(1):71-76. (2012). IF: 3.561
Theelen A, Martens J, Bosmans G, Houben R, Jager J, Rutten I, Lambin P, Minken AW, Baumert BG. Relocatable fixation systems in intracranial stereotactic radiotherapy: Evaluation of accuracy by serial CT scans and patient acceptance in a randomized manner. Strahlenther Onkol 188(1):84-90. (2012). IF: 3.561
Smits, A and Baumert BG. The Clinical Value of PET with Amino Acid Tracers for Gliomas WHO Grade II. Int J Mol Imaging:372509. (2011). IF: --.
van den Bent M, Wefel J, Schiff D, Taphoorn M, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman A, Gorlia T, Chamberlain M, Baumert B, Vogelbaum M, Macdonald D, Reardon D, Wen P, Chang S, Jacobs A. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 12(6):583-93 (2011) IF: 17.764
van de Langenberg R, de Bondt BJ, Nelemans PJ, Dohmen AJ, Baumert BG, Stokroos RJ. Predictors of Volumetric Growth and Auditory Deterioration in Vestibular Schwannomas Followed in a Wait and Scan Policy. Otol Neurotol. 32(2):338-44. (2011). IF: 2.065
Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Hassel MB, Kouri M, Valeinis E, van den Berge D, Collette S, Collette L, Mueller RP. Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study. J Clin Oncol 10;29(2):134-41. (2011). IF: 18.97
Lammering G, De Ruysscher D, van Baardwijk A, Baumert BG, Borger J, Lutgens L, van den Ende P, Ollers M, Lambin P. The Use of FDG-PET to Target Tumors by Radiotherapy. Strahlenther Onkol 186(9):471-81. (2010). IF: 3.567
Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frénay M, Grisold W, Grant R, Graus F, Hoang-Xuan K, Klein M, Melin B, Rees J, Siegal T, Smits A, Stupp R, Wick W. Guidelines on management of low-grade gliomas: report of an EFNS-EANO* Task Force. Eur J Neurol 17(9):1124-33. (2010). IF: 3.765
Musat E, Roelofs E, Bar-Deroma R, Fenton P, Gulyban A, Collette L, Stupp R, Weber DC, Davis JB, Aird E, Baumert BG. Dummy run and conformity indices in the ongoing EORTC Low Grade Glioma Trial 22033-26033: first evaluation of quality of radiotherapy planning. Radiother Oncol 95(2):218-24.(2010). IF: 4.337
Pijls-Johannesma M, van Mastrigt, Hahn SM, De Ruysscher D, Baumert BG, Lammering G, Buijsen J, Bentzen SM, Lievens Y, Kramar A, Gorlia T, Lambin P. A systematic methodology review of phase I radiation dose escalation trials. Radiother Oncol 95:135–141. (2010.) IF: 4.337
van Genugten JAB, Leffers P, Baumert BG, Tjon-a-Fat H, Twijnstra A. Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice J Neurooncol 96(2):249-57. (2010). IF: 2.929
Van de Langenberg R, de Bondt BJ, Nelemans PJ, Baumert BG, Stokroos R. Validation of vestibular schwannoma growth: volume assessment versus two-dimensional measurements. Neuroradiology.51(8):517-24. (2009). IF: 2.87
Pica A, Miller R, Villa S, Kadish SP, Anacak Y, Abusaris H, Ozyigit G, Baumert B, Zaucha R, Haller G and Weber D. The Results of Surgery, with or without Radiotherapy, for Primary Spinal Myxopapillary ependymoma: a Retrospective Study from the Rare Cancer Network. Int J Radiat Oncol Biol Phys 74(4):1114-20. (2009). IF: 4.503
Baumert BG and Stupp R. Symposium article. Low-grade glioma; a challenge in therapeutic options: the role of radiotherapy. Ann Oncol 19 (Suppl 7):vii217-vii222 (2008). IF: 6.452
Baumert BG, Brada MB, Bernier J, Kortmann R, Dehing-Oberije C, Collette L, Davis JB. EORTC 22972 trial:. EORTC 22972-26991/MRC BR10 trial: Fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost arm. Radiother Oncol. 88(2):163-72 (2008). IF: 4.337
Pasquier D, Bijmolt S, Veninga T, Rezvoy N, Villa S, Krengli M, Weber DC, Baumert BG, Canyilmaz E, Yalman D, Szutowicz E, Tzuk-Shina T, Mirimanoff RO; Rare Cancer Network. Atypical and Malignant Meningioma: Outcome and Prognostic Factors in 119 Irradiated Patients. A Multicenter, Retrospective Study of the Rare Cancer Network. Int J Radiat Oncol Biol Phys 71(5):1388-93. (2008). IF: 4.503
Saran F, Baumert BG, Creak AL, Warrington AP, Ashley S, Traish D and Brada M. Fractionated stereotactic radiotherapy in the management of recurrent or residual medulloblastoma/PNET. Pediatr Blood Cancer 50(3):554-60 (2008). IF: 1.948
Rutten I, Baumert BG, Seidel L, Kotolenko1 S, Collignon J, Kaschten B, Albert A, Martin D, Deneufbourg JM, Demanez JP, Stevenaert A. Long term follow-up reveals low toxicity of radiosurgery for vestibular schwannoma. Radiother Oncol 82(1):83-89 (2007). IF: 4.337
Mul VEM, van Geest AJ, Pijls-Johannesma MCG, Theys J, Verschueren TAM, Jager JJ, Lambin P, Baumert BG. Radiation-induced bullous pemphigoid: A systematic review of an unusual radiation side effect. Radiother Oncol 82(1):5-9 (2007). IF: 4.337
Baumert BG, Spahr MO, Von Hochstetter A, Landmann C, Beauvois S, Villa S, Kirschner MJ, Storme G, Thum P, Streuli HK, Lombriser N, Maurer R, Ries G, Bleher E, Willi A, Allemann J, Buehler U, Lütolf UM, Seifert B, Davis JB, Infanger M: The impact of radiotherapy in the treatment of desmoid tumors. The impact of radiotherapy in the treatment of desmoid tumours. An International Survey of 110 Patients. A study of the Rare Cancer Network. Radiat Oncol 2(1):12 (2007). Flagged as “HighLy accessed” on http://www.ro-journal.com/content/2/1/12. IF: 2.409
Weber DC; Miller RC; Villà S; Hanssens P; Baumert BG; Castadot P; Varlet P; Abacioglu U; Igdem S; Szutowicz E; Nishioka H; Hofer S; Rutz HP; Taghian A; Ozsahin M and Mirimanoff RO. Outcome and Prognostic Factors in Cerebellar Glioblastoma Multiforme in Adults: a Retrospective Study from the Rare Cancer Network. Int J Rad Oncol Biol Phys 66(1):179–186 (2006). IF: 4.503
Baumert BG, Rutten I, Dehing-Oberije C, Twijnstra A, Dirx MJM, Debougnoux-Huppertz RMTL, Lambin P, Kubat B: A pathology based substrate for CTV definition of radiosurgery for brain metastases. Int J Rad Oncol Biol Phys 66(1):187–19 (2006). IF: 4.503
Van Baardwijk A, Baumert B, Bosmans G, van Kroonenburgh M, Stroobants S, Gregoire V, Lambin PH, De Ruysscher D: The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev 32(4):245-60 (2006). IF: 6.811
Taphoorn MJB, Stupp R, Coens C, Osoba D, Curschmann J, Kortmann R, van den Bent MJ, Mason W, Mirimanoff RO, Baumert BG, Eisenhauer E, Forsyth P, Bottomley A: Health-related quality of life in a randomized controlled trial in glioblastoma patients: a joint study of the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group/Radiotherapy Group and National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). Lancet Oncol 6:937–44 (2005). IF: 17.764
Landert M, Baumert BG, Luetolf UM, Boesch MM, Landau K: Outcome of optic nerve sheath meningioma treated by fractionated stereotactic radiotherapy. J Neuro-Ophthalmol 25: 86–91 (2005). IF: 1.059
Baumert BG, Egli P, Studer S, Davis JB: Repositioning accuracy of fractionated stereotactic irradiation: Assessment of isocentre alignment for different dental fixations by using sequential CT scanning. Radiother Oncol 74(1):61-6 (2005). IF: 4.337
Baumert BG, Infanger M, Reiner B, Davis JB: A novel technique using customized templates for the application of fractionated interstitial brachytherapy to the tumour bed in soft tissue sarcomas located in the extremities. Clin Oncol (R Coll Radiol) 16(7):457-460 (2004). IF: 2.294
Baumert BG, Villà S, Studer G, Mirimanoff RO, Davis JB, Landau K, Ducrey N, Arruga J, Pica A: Early improvements in vision after fractionated stereotactic radiotherapy for primary optic nerve sheath meningioma. Radiother Oncol 72(2):169-174 (2004). IF: 4.337
Baumert BG, Norton IA, Lomax AJ, Davis JB: Dose conformation of Intensity Modulated Stereotactic photon beams, proton beams and intensity modulated proton beams for intracranial lesions. Int J Radiat Oncol Biol Phys 60(4): 1314-1324 (2004). IF: 4.592
Meier S, Baumert BG, Maier T, Wellis G, Burg G, Seifert B, Dummer R: Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie 27(2): 145-149 (2004). IF: 1.156
Baumann F, Bjeljac M, Kollias S, Baumert BG, Brandner S, Rousson V, Yonekawa Y, Bernays R: Combined Thalidomide and Temozolomide treatment in patients with glioblastoma multiforme. J NeuroOncol 67: 191–200 (2004). IF: 2.929
Stupp R and Baumert BG: Promises and controversies in the management of low-grade glioma. Editorial. Ann Oncol 14: 1695-1696 (2003). IF: 6.452
Baumert BG, Lutterbach J, Bernays R, Davis JB, Heppner FL: Fractionated stereotactic Radiotherapy boost after post-operative radiotherapy in high grade gliomas. Radiother Oncol 67(2): 183-190 (2003). IF: 4.337
Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, Lütolf UM, Steinert HC, Von Schulthess GK: Radiation treatment planning based on an integrated computer-assisted positron emission tomography (PET/CT): A feasability study. Int J Radiat Oncol Biol Phys 57(3): 853-8633 (2003). IF: 4.503
Baumert BG, Norton IA, Davis JB: Intensity Modulated Stereotactic radiotherapy versus stereotactic conformal radiotherapy for the treatment of meningeoma pre-dominantly located in the skull base. Int J Radiat Oncol Biol Phys 57(2): 580-592 (2003). IF: 4.503
Dizendorf E, Baumert B, von Schulthess GK, Lütolf UM, Steinert HC: Impact of 18F-FDG PET on staging and managing patients for radiation therapy. Journal Nuclear Medicine 44(1):24-29. Commentary by Hicks RJ and McManus MP 44(1):30-2 (2003). IF: 7.022
Saran FH, Baumert BG, Khoo VS, Adams EJ, Garré ML, Warrington AP, Brada M: Stereotactically guided conformal radiotherapy for progressive low grade gliomas of childhood. Int J Radiat Oncol Biol Phys 53(1):43-51 (2002). IF: 4.503
Jalali R, Loughrey C, Baumert B, Perks J, Warrington AP, Traish D, Ashley S, Brada M: High precision focussed irradiation in the form of fractionated stereotactic conformal radiotherapy (SCRT) for benign meningiomas predominantly in the skull base location. Clin Oncol (R Coll Radiol) 14(2):103-9 (2002). IF: 2.294
Ciernik IF, Baumert BG, Egli P, Lütolf UM: On-line correction of beam portals in the treatment of prostate cancer using an endorectal balloon device. Radiother Oncol 65(1):39-45 (2002). IF: 4.337
Baumert BG, Zagralioglu O, Davis JB, Reiner B, Lütolf UM, Ciernik IF: The use of a leg holder immobilization in 3D-Conformal radiation therapy of prostate cancer. Radiother Oncol 65(1):47-52 (2002). IF: 4.34
Gruber G, Laedrach K, Baumert B, Caversaccio M, Raveh J, Greiner R: Esthesioneuroblastoma: irradiation alone and surgery alone are not enough. Int J Radiat Oncol Biol Phys 54(2):486-491 (2002). IF: 4.503
Baumert BG, Lomax AJ, Miltchev V, Davis JB: A comparison of dose distributions of proton and photon beams in stereotactic conformal radiotherapy of brain lesions. Int J Radiat Oncol Biol Phys 49(5):1439-1449 (2001). IF: 4.503
Dizendorf E, Baumert B, von Schulthess GK, Lütolf UM, Steinert HC: [The impact of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) on planning of radiotherapy]. Terapevt Arkh 73(10):11-4 (2001). IF: 0.098
Huguenin P, Baumert B, Lutolf UM, Wight E, Glanzmann C: Curative radiotherapy in elderly patients with endometrial cancer. Patterns of relapse, toxicity and quality of life. Strahlenther Onkol 175(7):309-14 (1999). IF: 3.567
Huguenin PU, Taussky D, Moe K, Meister A, Baumert B, Lutolf UM, Glanzmann C: Quality of life in patients cured from a carcinoma of the head and neck by radiotherapy; the importance of the target volume. Int J Radiat Oncol Biol Phys 45(1):47-52 (1999). IF: 4.503
Alheit H, Saran FH, Warrington AP, Rosenberg I, Perks J, Jalali R, Shepherd S, Beardmore C, Baumert B, Brada M: Stereotactically guided conformal radiotherapy for meningiomas. Radiother Oncol 50(2):145-50 (1999). IF: 4.337
Baumgartner I, von Hochstetter A, Baumert B, Lütolf U, Follath F: Langerhans’-cell histiocytosis in adults. Med Pediatr Oncol 28:9-14 (1997). (Since 2003 Pediatric Blood Cancer, IF: 1.948)
Koch HK, Baumert B, Koch U, Oehlert M, Oehlert W: Prevalence of Campylobacter pylori as demonstrated by histology or CLO-test in different types of gastritis, a study in 5 clinically predefined types of patients. Path Res Pract 186:154-158 (1990). IF: 1.258
Briefe an den Editor
van den Bent MJ, Jaeckle K, Baumert B, Wick W.J. RTOG 9802: Good Wines Need Aging. J Clin Oncol 2013 Jan 7. [Epub ahead of print]
Mul VEM, Verschueren TAM, van Geest AJ, Baumert BG. Bullous pemphigoid (BP) induced by radiotherapy. Radiother Oncol 82(1):105. Correspondence. (2007). IF: 4.337
Publikationen in nationalen peer-reviewed Zeitschriften
Bromberg JEC, Gijtenbeek JMM, Westermann AM, Baumert BG, van der Maazen RWM, Kurt E, Wesseling P en Schouten-van Meeteren AYN. Medulloblastoom bij volwassenen: behandelprotocol Landelijke Werkgroep Neuro-Oncologie. Medulloblastoma in adults: treatment protocol Dutch Society for Neuro-Oncology. Ned Tijdschr Oncol 8:348-52 (2011)
De Ruysscher DKM, Van Baardwijk AM, Baumert BG, Lammering G, Borger JH, Lutgens LCHW, Van den Ende PLA, Öllers MC, Lambin P. The use of 18F-FDG PET to target tumours by radiotherapy. Tijdschr Nucl Geneesk 31(4):390-401. (2009)
Van Genugten JAB, Leffers P, Baumert B, Tjon-a-Fat H, Twijnstra A. Primair glioblastoma multiforme: effectiviteit van temozolomide in dagelijkse praktijk. Accepted for publication in Tijdschrift voor Neurologie en Neurochirurgie, 2009;110(3): 145-155 with Editorial by M.J. vd Bent: Het nut en de noodzaak van het evalueren van de eigen resultaten: gecombineerde chemo-radiotherapie. Tijdschrift voor Neurologie en Neurochirurgie 110(3):143-144 (2009)
Baumert BG, van den Berkmortel FWPJ. Internationale multicentrum fase-III-studie naar het effect van behandeling met temozolomide vergeleken met radiotherapie bij patienten met een laag-gradig glioom EORTC 22033-26033. Invited paper for: Ned Tijdschr Oncol 3:273-5. (2006)
Baumert B, Steinauer K, Lutolf UM: Therapie von ZNS-Metastasen. Ther Umsch 56(6):338-41 (1999)
Buchbeiträge, Proceedings.
Simpson JR, Drzymala RE, Rich KM and Baumert BG. Chapter: Cranial Stereotactic Radiosurgery, pp 335 – 363. In: Technical Basis of Radiation Therapy. Levitt, S.H.; Purdy, J.A.; Perez, C.A.; Poortmans, P. (Eds.). 5th ed Springer 2012.
Baumert BG. Chapter 4.2.2 Melanoma, Radiation, pp 311-316. In: Skin Cancer - A World-wide Perspective. Dummer, R.; Pittelkow, M.R.; Iwatsuki, K.; Green, A.; Elwan, N.M. (Eds.) Springer, 2011
Baumert BG, Stupp R. Is there a place for radiotherapy in low grade gliomas? In: Advances and Technical Standards in Neurosurgery. Low Grade Glioma. R. Schramm (ed.) SpringerWienNewYork. Adv Tech Stand Neurosurg. 2010;35:159-82.
Baumert BG. Wiederbestrahlung von primaeren Hirntumoren: Ueberleben, klinische Response und prognostische Faktoren. (Reirradiation of primary brain tumours: Survival, clinical response and prognostic factors). 6. Internationales Fortbildungssymposium KLINISCHE ONKOLOGIE 2007/08. University Hospital Dusseldorf e.V., Germany, 27.3.-30.3.2007. Proceedings booklet, Volume 3, pp 88-96. (2007)
Baumert BG. Recidief Hersenmetastasen: Behandelen of Niet? (Recurrent brain metastases: Retreat or not?) Symposium Neuro-Oncologie in de praktijk II: Metastasen in het zenuwstel - keuzes in behandeling. Den Haag, Netherlands, 9.2.2007. Proceedings booklet, pp 37-45.(2007)
Baumert BG, Stupp R. Radiation Therapy, Chemotherapy and Combined Chemoradiation in the Management of Malignant Glioma. 8th International Meeting on Progress in Radio-Oncology ICRO/OEGRO 8, Salzburg, Austria, May 16-19, 2007. Strahlenther Onkol, 183 (Suppl. 2);48-50: Ext. Abstr./ Proceedings E03. (2007)
Ciernik IF, Baumert B: Hochvolttherapie bei Hauttumoren und Lymphknotenmetastasen. In: Physikalische Therapiemassnahmen in der Dermatologie, Reinhard Dummer (ed.) Steinkopff Verlag (Springer) Darmstadt 2006.
Baumert B, Bodis S: Hochvolttherapie bei Hauttumoren. In: Physikalische Therapiemassnahmen in der Dermatologie, Reinhard Dummer (ed.) Steinkopff Verlag (Springer) Darmstadt (2003).
Brada M, Baumert B: Focal fractionated conformal stereotactic boost following radiotherapy of high-grade gliomas: A randomized phase III study. A joint study of the EORTC (22972) and the MRC (BR10). In: Wiegel , Hinkelbein W, Brock M, Hoell T (eds), Controversies in Neuro-Oncology. Front Radiat Ther Oncol Basel, Karger 33, pp. 241-243 (1999)
Baumert B, Lomax A, Miltchev V, Davis JB. A comparison of dose distributions for protons and conformal stereotactic photon beams for irradiation of brain lesions. Swiss Society of Radiobiology and Medical Physics (SGSMP) Zurich, Switzerland, 23.-24.9.1999. Proceedings SGSMP Zurich, pp 99 – 109 (1999).
Baumert B.: Hochvolttherapie bei Hauttumoren. In: Physikalische Therapie in der Dermatologie, Reinhard Dummer, Renato Panizzon (eds.) Blackwell Wissenschafts-Verlag Berlin. (1998).
Andere Publikationen
Intensitätsmodulierte Radiotherapie (IMRT). Ein grosser Schritt in der Strahlentherapie. Brigitta G. Baumert and J. Bernard Davis, in Neue Zűrcher Zeitung, Switzerland, 13.9.2000
Implementierung der intensitäts-modulierten Radiotherapie (IMRT) in die klinische Radio-Onkologie. Baumert B and Davis JB, Bulletin Krebsliga des Kantons Zürich, 2001
Published interview: Stereotactische radiotherapie: een bestraling die naadloos om de tumor sluit. Interview and article by Lidwien de Wit, in Select 48, December 2003 (Journal of University Maastricht and University Hospital Maastricht)
Intracraniële stereotactische radiotherapie. Elke millimeter telt. Baumert BG. Invited paper for: tijdschrift kanker 29(2):10-13, 2005
MGMT-methylatie: beste voorspeller van therapierespons. Verslag van 7e congres van de Europese Associatie voor Neuro-Oncologie (EANO), 14-17 september 2006, Wenen. Baumert BG, van den Berkmortel F. HealthDirect Agenda Neurologie 2006;2(4): 5
Baumert BG. Re-Irradiation in recurrent glioblastoma. Advanced Studies in Oncology. Johns Hopkins University. Vol.1, No. 1. July 2008. pp 19-22. (Continuing Medical Education http://www.jhasioncology.com)
Wanders S, Baumert B. Column: Beste practices in de regio. Stereotactische bestraling bij hersentumoren en hersenmetastasen. KNMG Journal District Limburg, Schelmenstreek 3, Februari 2009
Ho VKY, Kappelle AC, Reijneveld JC, Baumert BG, Bienfait HP, van de Kar-van der Meulen ML. Richtlijnen in de neuro-oncologie dienen als leiddraad - Oncologica nummer 04, 2010
Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frenay M, Grisold W, Grant R, Graus F, Hoang-Xuan K, Klein M, Melin B, Rees J, Siegal T, Smits A, Stupp R, Wick W. Guidelines on the Management of Low-grade Gliomas: EANO Task Force Report Eur Assoc Neurooncol Mag 2011;1(1): 37–44. Online publication
Interview: Neuro-oncologie, boeiende ontwikkelingen. Brigitta Baumert, interview met een gedreven radiotherapeut. Published online on AZM website, Oncologycentre News. September 2011
Interview: Radiation-Oncology – a fascinating field. Published in: Brain Tumour. IBTA (International Brain Tumour Alliance) World Edition 2011. pp: 54-55, 2011
Interview with Dr Brigitta Baumert about the EORTC Low-Grade Glioma Trial. Abacioglu U. European Association of NeuroOncology Magazine 2012; 2 (3) 147-148. Published online www.kup.at/journals/eano/index.html